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ALTERED SCLEROSTIN SYNTHESIS IN CARTILAGE AND BONE CONTRIBUTE
OA PATHOLOGY
B. Chan1, E. Fuller1, L. Rowley2, D. Belluoccio2, S. Smith1, M. Cake3,
R. Read3, J. Bateman2, P. Sambrook1, C.B. Little1
1Kolling Inst. of Med. Res., Univ. of Sydney, St Leonards, Australia; 2Murdoch
Childrens Res. Inst., Parkville, Australia; 3Murdoch Univ., Perth, Australia
Introduction: Canonical Wnt signalling and increased β-catenin activity
have been implicated in the process of cartilage degradation in osteoarthri-
tis (OA). Increased Wnt-induced signalling protein 1 (WISP1) in OA cartilage
induces cartilage degradation by upregulating matrix metalloproteinases
(MMPs) and aggrecanases (ADAMTS-4 and ADAMTS-5). Wnt signalling is
inhibited by endogenous antagonists dickkopf-1 (DKK1), secreted frizzled-
related proteins (sFRP) and sclerostin (SOST). Despite increased chondrocyte
β-catenin promoting cartilage degradation, insuﬃciency of sFRPB failed to
alter OA cartilage damage in mice, and inhibition of DKK1 reduced rather
than increased cartilage damage in a surgical model of OA in rats. These
conﬂicting results demonstrate the complexity of Wnt-β-catenin regula-
tion. SOST is a potent Wnt-β-catenin antagonist and a key regulator of
bone metabolism but no previous studies have investigated its role in OA
pathology.
Methods: SOST, WISP-1 and β-catenin were immuno-localised in osteo-
chondral sections of surgically-induced OA in sheep and mice, as well as
human tibial plateaus obtained at arthroplasty for OA. Expression of Sost,
Wisp-1, β-catenin, Lrp-5/6, Dkk1, Mmp-1 & -13, Adamts-4 & -5, Timp-1 &
-3, aggrecan and collagen II by chondrocytes in OA, and with stimulation
by 10ng/ml interleukin-1α (IL-1) or 100ng/ml tumor necrosis factor-α (TNF)
in culture, was quantiﬁed by real-time RT-PCR. The effect of 25-500ng/ml
rhSOST on cartilage degradation and chondrocyte gene expression was
examined in explant culture.
Results: Contrary to being osteocyte-speciﬁc, Sost mRNA was expressed by
articular chondrocytes in all species, and was upregulated in OA in mice and
by IL-1 but not TNF in culture. Chondrocyte SOST protein was signiﬁcantly
increased only in the focal area of cartilage damage in surgically-induced
OA in sheep and mice, as well as end-stage human OA. In contrast,
osteocyte SOST was focally decreased in the subchondral bone in OA in
association with increased bone sclerosis. SOST was biologically active in
chondrocytes, increasing expression of Mmp-13 from as early as 4 hours
and maintained to 24 hours. At 48 hours, exogenous SOST decreased mRNA
levels of aggrecan and type II collagen, inhibited Wnt-β-catenin signalling
and down-regulated Mmp-13, Adamts-5 and Timp-1 and Timp-3 expres-
sion. SOST augmented IL-1’s stimulatory effects on chondrocyte Mmp-1,
Adamts-4 and Adamts-5, and its inhibition of aggrecan and collagen II
expression.
Conclusions: Taken together, this data suggests that SOST may actively
participate in the pathological progression of OA by affecting both cartilage
and subchondral bone. The differential change in SOST in cartilage and
subjacent bone highlight the potential tissue/cell speciﬁc regulation of
Sost, and the opposing effects of altering Wnt-β-catenin activity in bone
and cartilage. Overall the effects of SOST in cartilage are pro-catabolic,
with inhibition of aggrecan, collagen II and Timp expression, and acute
upregulation of Mmp-13. In bone, SOST increases osteoblast activity and
bone formation, and inhibition of SOST and DKK1 have potential in treating
osteoporosis. In light of this and the multiple potential mechanisms of
action of SOST, it will be important to determine what effect its inhibition
may have on progression of both bone and cartilage changes in OA in vivo.
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INDUCTION OF INFLAMMATORYMEDIATORS AND MATRIX
DEGRADATION IN ARTICULAR CARTILAGE BY TENASCIN-C AND TLR4
SIGNALING
L. Patel, W. Sun, K.E. Georgiadis, E.A. Morris, C.R. Flannery,
P.S. Chockalingam
Pﬁzer, Cambridge, MA
Purpose: Tenascin-C (TNC) is a modular, multifunctional extracellular ma-
trix glycoprotein that is involved in tissue injury and repair processes. TNC
plays a major role in cell adhesion, migration, proliferation, and cellular
signaling. TNC stimulates the production of pro-inﬂammatory cytokines in
human macrophages and synovial ﬁbroblasts through activation of Toll-like
receptor-4 (TLR4) (Midwood et al, Nat Med 2009). We have previously
demonstrated that elevated levels of TNC may be a sensitive biomarker of
joint disease/injury in synovial ﬂuids from human patients and preclinical
animal models. In the current study, we compared cartilage mRNA and
protein levels of TNC under normal and diseased conditions, and evaluated
the capacity for TNC and TLR signaling pathways to induce inﬂammatory
mediators and matrix degradation in articular cartilage.
Methods: Specimens of human osteoarthritic (OA) cartilage were obtained
from patients undergoing knee replacement surgery (New England Baptist
Hospital), and non-OA human cartilage was from tissue donors with no
history of joint disease (NDRI). TNC was measured in human cartilage
extracts and bovine cartilage explant culture media using an ELISA kit
(IBL). Human TNC was from Millipore, and rough LPS was from Axxora.
Bovine cartilage explant cultures were used to study the effect of IL-1α on
TNC expression, and the impact of TNC and LPS treatments on the release
of sulfated glycosaminoglycan (sGAG). Chondrocyte/explant conditioned
media were also assayed using ELISA kits for IL-6 (Thermo Scientiﬁc), PGE2
(R&D Systems) and nitrate (Cayman). TNC, ADAMTS4, MMP13, aggrecan,
type II collagen and GAPDH Taqman assays were performed using one step
RT-PCR with primer probes from Applied Biosystems. TAK242, a speciﬁc
TLR4 inhibitor (Takashima et al, Br J Pharmacol 2009), was synthesized and
tested in chondrocyte and explant culture studies.
Results: Human OA cartilage extracts had ∼8-fold more TNC protein
relative to non-OA cartilage extracts. TNC mRNA expression was elevated
∼6-fold in human OA cartilage compared to non-OA cartilage. Treatment
of human OA chondrocytes with TNC (10μg/ml) or LPS (1μg/ml) signiﬁ-
cantly induced the production of IL-6 and PGE2 (∼10,000- and ∼5,000-fold
increase, respectively), and nitrate release was also upregulated (up to
5-fold). Induction of IL-6, PGE2, and nitrate secretion was dose-dependently
reduced by addition of TAK242 (0.01-1μM). In bovine chondrocyte cultures,
expression of ADAMTS4 and MMP13 mRNA was induced by TNC and LPS
(∼28- and ∼58-fold increase, respectively), whereas type II collagen and
aggrecan expression was downregulated. TNC- and LPS-dependent modu-
lation of gene expression was also suppressed by the addition of TAK242.
Addition of TNC or LPS stimulated the release of sulfated glycosaminogly-
can from bovine explants, and this degradative response was inhibited by
TAK242. To demonstrate that preparations of TNC were not contaminated
with LPS, heat killed TNC served as a negative control in these studies
and did not cause any effect. Addition of ILα to bovine explant cultures
increased TNC release in a dose dependent manner indicating synthesis of
TNC by chondrocytes in response to inﬂammatory stimuli.
Conclusions: Elevated levels of TNC protein and mRNA expression in
OA cartilage correlated with our previous observations of increased TNC
levels in the synovial ﬂuid of OA patients (mean of 0.85μg/ml; range of
0.07-3.72μg/ml) compared to reference subjects (mean of 0.12μg/ml; range
of 0.003-0.59μg/ml). TNC was recently identiﬁed as a DAMP (damage-
associated molecular pattern) activating TLR4 in inﬂammatory diseases. In
the current studies, TNC or LPS caused an elevation in matrix degrading
enzymes and accelerated matrix degradation through TLR4 signaling in
articular cartilage, suggesting that therapeutic strategies impacting this
pathway may be applicable for the treatment of joint disorders.
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ALLELIC EXPRESSION ANALYSIS OF THE GENES WITHIN THE
CHROMOSOME 7q22 OA SUSCEPTIBILITY LOCUS REVEALS EVIDENCE FOR
FUNCTIONAL POLYMORPHISM IN COG5
A.W. Dodd, N. Wreglesworth, E.V. Raine, A. Gravani, J. Loughlin
Newcastle Univ., Newcastle upon Tyne, United Kingdom
Purpose: A highly signiﬁcant association of an OA susceptibility locus has
recently been reported at chromosome 7q22, to a region of high linkage
disequilibrium (LD) encompassing six known genes: PRKAR2B, HBP1, COG5,
GPR22, DUS4L and BCAP29. It is becoming increasingly apparent that most
common disease susceptibility loci harbour causal polymorphisms that
regulate expression of the gene - so called expression quantitative trait loci
(eQTLs). As a means of dissecting apart the six OA candidates from within
the high LD block we have searched for eQTLs that could account for the
OA association signal.
Methods: Using a panel of human cell lines, including chondroytic, os-
teoblastic, and lipocytic cells, and OA patient joint tissues, including
cartilage, meniscus, fat pad, synovium, tendon, ligament and osteophyte,
we measured both the overall amount of gene expression, by quantitative
real-time PCR, and the allelic expression of the genes, using transcript SNPs
identiﬁed by direct DNA sequencing and an allelic expression assay that
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can sensitively distinguish mRNA output from each copy of an autosomal
gene.
Results: Five of the six genes showed abundant expression in cell lines
and in joint tissues, the exception being GPR22, which had an expression
level on average at least 100 fold lower than that seen for the other
genes. The gene showing the highest level of expression in any tissue
tested was PRKAR2B in fat pad whilst in cartilage the gene showing the
highest expression level was COG5. Intriguingly COG5, HBP1, PRKAR2B and
DUS4L all showed signiﬁcantly elevated expression levels in OA cartilage
compared to cartilage from control patients who had undergone joint
replacement surgery due to hip fracture. Our allelic expression imbalance
experiments revealed the existence of eQTLs in COG5, with allelic ratio
differences ranging up to 1.3 (P < 0.003) using transcript SNPs that have
high LD with the SNPs used in the association mapping of the 7q22 locus.
Conclusions: COG5 merits further investigation as a locus harbouring
cis-acting polymorphism that may account for some of the OA association
signal located at 7q22. Further analysis of transcript SNPs for COG5 and for
the other genes may highlight additional eQTLs of functional relevance.
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REDUCED EXPRESSION OF COLLAGEN TYPE IX IN HUMAN
OSTEOARTHRITIC CHONDROCYTES IS ASSOCIATEDWITH EPIGENETIC
SILENCING BY DNA HYPERMETHYLATION
K. Imagawa1,2, M.C. de Andrés1, K. Hashimoto3, E. Itoi2, R.O. Oreffo1,
H.I. Roach1
1Univ. of Southampton, Southampton, United Kingdom; 2Tohoku Univ., Sendai,
Japan; 3Hosp. for Special Surgery, New York, NY
Purpose: Cartilage matrix composition and integrity play a critical role
in articular cartilage function and understanding the mechanisms and
consequences of altered articular cartilage matrix integrity is pivotal in
diseases such as Osteoarthritis (OA). Although only 1% to the total collagen
of mature cartilage consists of collagen type IX, this collagen is present
on the surface of type II collagen and binds covalently to two collagen
II molecules and to cartilage oligomeric matrix protein, and, critically, is
pivotal in the integrity and stability of articular cartilage.
Gene expression is regulated by both epigenetic and non-epigenetic mech-
anism with DNA methylation the main heritable component in epigenetics
Our previous studies have implicated a role for epigenetic mechanisms in
the pathogenesis of OA. The aim of this study was to investigate whether
increased DNA methylation is associated with loss of COL9A1 expression
in OA chondrocytes.
Methods: Human chondrocytes were isolated from the articular cartilage of
femoral heads obtained from fracture neck of femur (NOF)(controls, 10 pa-
tients) or total hip replacements (OA,12 patients). For control chondrocyte
populations, only deep zone cartilage was used, providing healthy, albeit
aged, chondrocytes. For OA chondrocyte populations, only the surface zones
were dissected, shown previously to contain typical OA chondrocytes with
an altered ‘degradative’ phenotype. Primary chondrocytes from the NOF
samples (N=6) were cultured for 5 weeks in 2 groups: without treatment
(control culture); and 2uM 5-aza-2’deoxycitidine (5Aza-C). Total RNA and
genomic DNA were extracted simultaneously from each sample. Gene ex-
pression for COL9A1 was determined using SybrGreen-based qRT-PCR. The
% DNA methylation in the COL9A1 promoter was quantiﬁed after bisulﬁte
modiﬁcation with a pyrosequencer (Biotage).
Results: High expression of COL9A1 was found in the control samples. In
contrast, within the OA chondrocyte population, expression was signiﬁ-
cantly down-regulated. COL9A1 expression in OA patients was 6000-fold
lower than in control patients. To determine whether the loss of COL9A1
expression in OA cartilage was associated with epigenetic silencing by DNA
hypermethylation, the DNA methylation status was quantiﬁed. A total of 7
out of 8 CpG sites of the COL9A1 promoter (AF036110) were analysed. We
found 6 CpG sites were statistically signiﬁcantly hypermethylated in OA
patients compared to control patients.
Interestingly, compared to preculture NOF samples, COL9A1 expression in
control culture was abolished, and 3 CpG sites were statistically signiﬁ-
cantly hypermethylated in control culture. However, COL9A1 expression in
5 Aza-C groups were 7-fold higher than the control culture. 3 CpG sites
were statistically signiﬁcantly hypomethylated in 5 Aza-C groups compared
to control culture.
Conclusions: This is the ﬁrst demonstration that, in OA, hypermethylation
is associated with down-regulation of COL9A1 expression a keychondro-
cyte gene. While control culture of chondrocytes resulted in a altered
methylation status of the COL9A1 promoter and COL9A1 expression was
abolished, these studies show we could prevent hypermethylation by
5Aza-C treatment and maintain COL9A1 expression.
In summary, the present study demonstrate the pivotal role of epigenetic
changes in OA that involve not only hypomethylation and consequent ac-
tivation of aberrant genes, but, also, hypermethylation leading to silencing
of a of gene expression in a chondrocytic genes lacking CpG islands. No
doubt other such genes will be identiﬁed in the future but the therapeutic
implications are compelling in OA.
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THE OSTEOARTHRITIS-ASSOCIATED GENE GDF5 IS UNDER EPIGENETIC
REGULATION IN PATIENT TISSUES AND IN A RANGE OF HUMAN CELL
LINES
L.N. Reynard, A. Gravani, J. Loughlin
Newcastle Univ., Newcastle upon Tyne, United Kingdom
Purpose: Growth and Differentiation Factor 5 (GDF5) is involved in the
development and repair of synovial joint tissues. Polymorphisms within the
GDF5 gene have been identiﬁed that are associated with OA susceptibility,
including the rs143383 SNP located in the 5’UTR, with the risk-associated
T-allele of this SNP being expressed at lower levels relative to the C-allele.
This suggests that even a small decrease in GDF5 expression in cartilage
and other joint tissues increases the risk of developing OA. Several studies
have indicated that loss of normal epigenetic gene regulation may play a
role in the pathogenesis of OA, with chondrocytes from OA patients having
disrupted patterns of DNA methylation that are associated with abnormal
gene expression. We therefore examined whether GDF5 is aberrantly
methylated in OA and what affect this had on GDF5 expression. This is
particularly relevant in light of the fact that the C-allele of rs143383, which
is the ancestral allele, is part of a CpG dinucleotide, as is the C-allele
of GDF5 SNP rs143384, which is also located in the 5’UTR and which
has previously been show to modulate the effect of rs143383 on GDF5
expression. As CpG dinucleotides, both of these SNPs are potentially under
epigenetic regulation.
Methods: SW1353 chondrosarcoma cells and human articular chondro-
cytes (HACs) from OA patients were cultured for several passages with the
demethylating agents 5-aza-2’deoxycytidine (AZA) and RG108 respectively.
Nucleic acid was extracted from treated cells, joint tissues of OA and
fractured-neck-of-femur (NOF) control patients undergoing total joint re-
placement and CH8, SW1353, SaOS-2 and COLO205 cell lines. Methprimer
and PSQ assay design software were used to design primers within the pro-
moter and the 5’UTR of GDF5. DNA was bisulphite converted, PCR ampliﬁed
and then either cloned and sequenced or subject to pyrosequencing. Se-
quences from individual clones were analysed using BiQ analyser software
and statistical differences in methylation calculated using Fisher’s exact
test. RNA was reverse transcribed and the expression of GDF5 examined by
qRT-PCR.
Results: Bisulphite sequencing of the 1.5kb region upstream of the GDF5
transcription start site and the 5’UTR identiﬁed several differentially
methylated CpG sites; these sites were hypermethylated in non-expressing
COLO205 cells (75.78% overall methylation) and hypomethylated in highly
expressing CH8 articular chondrocytes (26.6% methylation). These CpG
sites were also hypomethylated in GDF5-expressing synovial joint tissues
from an OA patient relative to blood lymphocytes, which do not express
GDF5. The CpG sites created by the C-alleles at rs143383 and rs143384
were found to be methylated in both cell lines and HACs, indicating that
these SNPs may have a role in epigenetic as well as genetic regulation
of GDF5 expression. GDF5 was upregulated in SW1353 osteosarcoma cells
after exposure to the DNMT inhibitor 5-aza-2’-deoxycytidine for one (6.23
fold) or two passages (17.69 fold); this was accompanied by a decrease
in methylation of the CpG island and 5’UTR. Treatment of HACs with the
demethylating agent RG108 also modulated GDF5 expression.
Conclusions: Our results indicate that the GDF5 gene is epigenetically
regulated by DNA methylation in both cell lines and tissues of the articu-
lating joint and that the OA-associated SNP rs143383 has a role in genetic
and epigenetic regulation of GDF5. Furthermore, GDF5 is upregulated in
SW1353 chondrosarcoma cells and HACs exposed to DNA demethylating
agents. Future work will examine the potential role of GDF5 methyla-
tion in osteoarthritis development and progression by comparing GDF5
methylation in normal and OA cartilage.
